Prognostic Value of KK-LC-1 in Breast Cancer

This research involved three independent study cohorts. The first cohort included six pairs of fresh triple-negative breast cancer and adjacent cancer tissues obtained from the China Medical University affiliated hospital between January 2020 and June 2020. These six pairs of samples were used to detect KK-LC-1 expression using western blotting. The second cohort included 481 breast cancer operation specimens obtained from the China Medical University affiliated hospital between April 2006 and November 2014. These specimens were used to detect KK-LC-1 expression using immunohistochemistry. Patient information included age, T grade, N grade, menopausal status, date of operation, date of local recurrence and distant metastasis, date of death, and molecular subgroups. All specimens were pathologically verified to have invasive ductal carcinoma. None of the patients received radiotherapy or chemotherapy before the operation and had complete postoperative follow-up data. Disease-free survival (DFS) refers to the time from operation completion to recurrence or distant organ metastasis. Overall survival (OS) refers to the time from operation completion to the death of a patient. If the patient did not develop local recurrence, distant metastasis, or the patient did not die, the last follow-up time was the endpoint of survival.
The third cohort included 126 triple-negative breast cancer patient specimens obtained from the China Medical University affiliated hospital between October 2012 and December 2014. These specimens were utilized to detect the expression of KK-LC-1, MAL2, MUC1, and CLDN2 by immunohistochemistry. This study was approved by the China Medical University Ethics Committee.